Guangdong Taiantang Pharmaceutical Co., Ltd.

SZSE:002433 Voorraadrapport

Marktkapitalisatie: CN¥207.0m

This company listing is no longer active

This company may still be operating, however this listing is no longer active. Find out why through their latest events.

De vertaling van deze pagina is experimenteel en in ontwikkeling. Uw is welkom!

Guangdong Taiantang Pharmaceutical Balans Gezondheid

Financiële gezondheid criteriumcontroles 3/6

Guangdong Taiantang Pharmaceutical has a total shareholder equity of CN¥340.5M and total debt of CN¥780.9M, which brings its debt-to-equity ratio to 229.3%. Its total assets and total liabilities are CN¥3.3B and CN¥2.9B respectively.

Belangrijke informatie

229.3%

Verhouding schuld/eigen vermogen

CN¥780.92m

Schuld

Rente dekkingsration/a
ContantCN¥93.59m
AandelenCN¥340.53m
Totaal verplichtingenCN¥2.94b
Totaal activaCN¥3.28b

Recente financiële gezondheidsupdates

Geen updates

Recent updates

Little Excitement Around Guangdong Taiantang Pharmaceutical Co., Ltd.'s (SZSE:002433) Revenues As Shares Take 57% Pounding

May 01
Little Excitement Around Guangdong Taiantang Pharmaceutical Co., Ltd.'s (SZSE:002433) Revenues As Shares Take 57% Pounding

Analyse van de financiële positie

Kortlopende schulden: 002433's short term assets (CN¥1.1B) do not cover its short term liabilities (CN¥2.3B).

Langlopende schulden: 002433's short term assets (CN¥1.1B) exceed its long term liabilities (CN¥608.5M).


Schuld/ eigen vermogen geschiedenis en analyse

Schuldniveau: 002433's net debt to equity ratio (201.8%) is considered high.

Schuld verminderen: 002433's debt to equity ratio has increased from 43.3% to 229.3% over the past 5 years.


Balans


Analyse van de cashflow

Voor bedrijven die in het verleden gemiddeld verliesgevend zijn geweest, beoordelen we of ze ten minste 1 jaar kasstroom hebben.

Stabiele cash runway: 002433 has sufficient cash runway for more than a year based on its current free cash flow.

Voorspelling contante baan: 002433 has sufficient cash runway for 2.1 years if free cash flow continues to grow at historical rates of 26.8% each year.


Ontdek gezonde bedrijven